Get the Stockscreener App
2.86
0.35%
-0.01
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria
Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Embraces Market with New Sales Agreement - TipRanks
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Galmed Phar stock hits 52-week low at $2.73 amid challenges - Investing.com Australia
500: Something went wrong - Investing.com Canada
Galmed Pharmaceuticals Amends Equity Purchase Agreement - TipRanks
Acyl CoA Desaturase Market Current Status and Future Prospects - IndiaPolitics.com
galmed pharmaceuticals ltd. Earnings dates - RTTNews
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Above 50-Day Moving Average of $4.52 - Defense World
United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
(GLMD) Long Term Investment Analysis - Stock Traders Daily
Galmed reports positive results for Aramchol in NASH study By Investing.com - Investing.com Australia
Galmed reports positive results for Aramchol in NASH study - Investing.com India
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire
Post-Trade Analysis: Galmed Pharmaceuticals Ltd (GLMD) Slides -13.90, Closing at 8.05 - The Dwinnex
Take off with Galmed Pharmaceuticals Ltd (GLMD): Get ready for trading - SETE News
Understanding GLMD stock ratios for better investment decisions - US Post News
GLMD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward - Stocks Telegraph
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - GlobeNewswire
Galmed Pharmaceuticals Calls for Capital Increase Vote - TipRanks
Galmed expands drug development to cancer and heart diseases - Investing.com
Galmed surges on plans to expand into cancer and heart disease drug development - XM
Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why - Benzinga
Market Insights: Galmed Pharmaceuticals Ltd (GLMD)’s Notable Drop of -54.30, Closing at 6.90 - The Dwinnex
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - PR Newswire
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases | GLMD Stock News - StockTitan
B. Riley FBR Downgrades Galmed Pharmaceuticals Ltd (GLMD) to a Neutral from a Buy - Knox Daily
Galmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing Price - MarketWatch
US Stocks Mixed; General Mills Posts Upbeat Earnings - Benzinga
A new trading data show Galmed Pharmaceuticals Ltd (GLMD) is showing positive returns. - SETE News
Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze - TipRanks
Those who invested in Neuren Pharmaceuticals (ASX:NEU) three years ago are up 576% - Yahoo Finance
Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat
Gold Edges Lower; US Homebuilder Sentiment Rises For September - Benzinga
Galmed Pharmaceuticals Surges After Regaining Nasdaq Compliance - MarketWatch
Galmed Pharmaceuticals Ltd’s Banking’s 100-Day Moving Average at 4.01: Will the Stock Break Through? - The InvestChronicle
Stock Market news: Galmed Pharmaceuticals soars 283%, Intel up 3.49%, while Tupperware plunges 57% - Business Upturn
Express Scripts sues FTC and demands drug pricing report retraction - Yahoo! Voices
With its newest mac and cheese, Stouffer's expands beyond the freezer aisle to supermarket shelves - Yahoo! Voices
Merit Medical touts positive six-month data from WAVE trial - Yahoo! Voices
Lunds & Byerlys digitizes refrigeration compliance management - Yahoo! Voices
Crude Oil Gains Over 1%; US Business Inventories Increase In July - Benzinga
Philip Morris to sell Vectura for $198 million after health shift criticism - Yahoo Finance
Why Shares of Gannett Are Soaring Today - Yahoo Finance
Galmed Pharma stock hits 52-week high at $10.51 - Investing.com
FanDuel Parent Buys Italian Gaming Operator Snai for $2.56 Billion - Yahoo! Voices
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):